A Rh negative G4P3+O has an antibody level of 15 IU/ml (IAT 1 :32) at 27 weeks.What is the most appropriate next step in the management?
**Core Concept**
The management of a Rh negative pregnant woman with a high titer of anti-D antibodies requires careful consideration to prevent hemolytic disease of the newborn (HDN). The presence of anti-D antibodies indicates sensitization to Rh-positive blood, which can lead to hemolysis of the fetus's red blood cells if not managed properly.
**Why the Correct Answer is Right**
The patient's antibody level of 15 IU/ml and IAT 1:32 indicates significant sensitization. The American College of Obstetricians and Gynecologists (ACOG) recommends administration of Rh immune globulin (RhIg) to Rh-negative women with a high risk of HDN. RhIg helps to prevent further sensitization and reduce the risk of HDN. In this case, the patient is already sensitized, but RhIg may still be beneficial to prevent further antibody production and potential HDN.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect as there is no mention of the need for immediate delivery or cesarean section. The patient's gestational age is 27 weeks, and the primary concern is preventing further sensitization and HDN.
* **Option B:** This option is incorrect as there is no indication of fetal distress or significant hemolysis. The patient's antibody level is high, but the fetus's condition is not immediately compromised.
* **Option C:** This option is incorrect as there is no mention of the need for intrauterine transfusion or immediate delivery. The patient's gestational age is 27 weeks, and the primary concern is preventing further sensitization and HDN.
**Clinical Pearl / High-Yield Fact**
RhIg is typically administered between 28 and 30 weeks of gestation to Rh-negative women with a high risk of HDN. However, in cases where the patient is already sensitized, as in this scenario, RhIg may still be beneficial to prevent further antibody production and potential HDN.
**Correct Answer:** C. Administer Rh immune globulin to prevent further sensitization and HDN.